糖尿病治療薬の世界市場2016-2026

◆英語タイトル:Diabetes World Drug Market Report 2016-2026
◆商品コード:VGAIN60707
◆発行会社(調査会社):visiongain
◆発行日:2016年6月
◆ページ数:258
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥283,858見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥425,858見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥709,858見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、糖尿病治療薬の世界市場について調査・分析し、糖尿病治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
1. レポート概要

2. 糖尿病治療薬の世界市場:概要

3. 糖尿病治療薬の世界市場 2016-2026

4. ヒトインスリンおよび類似体 2016-2026

5. ジペプチジルペプチダーゼ4阻害薬(DPP-4)市場 2016-2026

6. スルホニル尿素薬市場 2016-2026

7. グルカゴン様ペプチド-1(GLP-1)受容体作動薬市場 2016-2026

8. αグルコシダーゼ阻害薬市場 2016-2026

9. メグリチニド市場 2016-2026

10. チアゾリジンジオン市場 2015

11. ナトリウム・グルコース共役輸送体(SGLT2)阻害薬市場 2016-2026

12. ビグアナイド薬市場 2016-2026

13. 糖尿病治療薬の国別市場 2016-2026

14. 糖尿病治療薬市場の研究開発パイプライン 2016

15. 糖尿病治療薬:世界の産業、市場および研究開発分析 2016-2026

16. 調査インタビュー

17. 研究・分析の結論
【レポートの概要】

Treating diabetes – benefit your influence by finding new R&D trends and sales prospects
Discover the future of antidiabetic medicines. For those treatments, you will receive diabetes market size and revenue projections. You will learn the future potential by exploring research and development pipelines. And you will be able to assess results, trends, technologies, therapies and future business opportunities.

Visiongain’s updated report forecasts those revenues to 2026 at overall world market, submarket, product and national level. You can stay ahead with clear market data for treating human diabetes, finding commercial outlooks to benefit your research, analysis and authority.

See what’s possible for treating diabetes mellitus. Read on, then, to explore treatment of those metabolic diseases, also finding those medicines’ predicted revenue.

Forecasts to 2026 and other analyses explain and predict the diabetes treatment market
Why miss crucial data that you need? Why struggle to find information? Instead our report gives you revenue forecasts to 2026, also with recent results, growth rates, market shares and discussions.

Our 258 page report provides 76 tables and 141 figures, and an interview with Professor Mark Baker, Director of the Centre for Clinical Practice (CCP) at the National Institute of Healthcare Excellence.

Our work’s purpose is to predict that industry’s future, helping your research, analyses and decisions. See how you can benefit your reputation for commercial insight, also helping your influence.

Diabetes therapies hold some of the strongest prospects for pharmaceutical companies. See why and what sales are possible, finding where money and growth opportunities exist.

The following sections show how our new investigation benefits your work.

Forecasting of the world diabetes drugs market and its segments – what does the future hold?
What are the secrets of the industry’s progress? Where’s it heading? Discover in our report overall world revenue prediction to 2026 for antidiabetic pharmaceuticals, with discussions.

Also find individual revenue forecasts to 2026 for nine therapeutic submarkets at world level:
• Human insulins and analogues
• Dipeptidyl peptidase-4 inhibitors (DPP-4)
• Biguanides
• Glucagon-like peptide-1 receptor agonists (GLP-1)
• Sulfonylureas.

And these treatment categories:
• Thiazolidinediones
• Alpha-glucosidase inhibitors
• Meglitinides
• Sodium-glucose co-transporter-2 inhibitors (SGLT2)
• Other agents (grouped).

You can assess the outlook for revenue expansion, learning where you can profit. Find the diabetes market size from 2016-2026. You can investigate the competition and rising sales. And you will examine technological, clinical and commercial possibilities.

Also you will find top medicines’ revenue potentials.

Predictions of leading products’ sales – see what’s possible, and where you can gain
How will individual drugs for elevated blood sugar perform to 2026 at world level? Our study forecasts revenues of 31 leading products. Assess top brands, including these agents:
• Lantus
• Januvia
• NovoLog and NovoMix
• Levemir
• Humalog
• Victoza
• Janumet
• Humulin.

There you will find drugs and the years with highest predicted sales. You can also examine competitors. So discover what’s happening for lowering blood glucose and controlling its level, understanding challenges, trends, competition and opportunities for revenue expansion.

Our work also gives geographical sales predictions.

National markets – what is the outlook for treatment demand and revenues?
In developed and developing countries, many opportunities for producers and sellers of diabetes-treating medicines will occur from 2016 to 2026. See where, how and what’s possible.

Our analyses show you individual revenue forecasts to 2026 for 11 national markets:
• United States (US)
• Japan
• EU leaders – Germany, France, the UK, Italy and Spain (EU5)
• BRIC nations – Brazil, Russia, India and China.

There you can explore the market progress, needs and opportunities. What events will change that market and the outlook for payers and patients? Our work shows you, discussing the trends and demands.

Events affecting developers, producers and sellers of those metabolic treatments
Our report also explains issues, forces and events affecting the antidiabetics industry and market from 2016, including these influences:
• Drug approvals and R&D in human insulins and analogues, DPP-4 inhibition, GLP-1 therapies, sodium glucose co-transporter mechanisms and other candidates
• Governmental investment and collaboration between pharmaceutical companies
• Combination therapies for type 2 diabetes
• Competition from biosimilars and generic drugs – approvals and product launches.

And these issues are also assessed, among others:
• Disease incidence and prevalence
• Risk factors – obesity and pre-diabetes, related metabolic conditions
• Drug delivery – technologies for introducing insulin and oral drugs
• New classes of antidiabetic medications and regulatory challenges
• Type 1 diabetes vaccine – new treatment approaches, including disease prevention.

Diabetes management forms a leading use for biological drugs, now dominant in the pharmaceuticals industry. There you can investigate what stimulates and restrains that biopharma, affecting its results. Also you will see the prospects for small-molecule therapies.

Analysis of firms and potential for rising sales – what overall revenues are possible?
What happens next? Our study predicts the world market will rise to $75bn in 2020, with high, expanding revenues from 2016 to 2026. Discover what’s possible.

Our analysis covers organisations shaping that industry:
• Novo Nordisk
• Eli Lilly
• Novartis
• AstraZeneca
• Merck & Co.

We also investigate these leading companies, among other firms, including specialists in metabolic disorders:
• Boehringer Ingelheim
• Takeda
• Sanofi
• Bayer
• Pfizer.

From 2016, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from those medications.

【レポートの目次】

1. Report Overview
1.1 Introduction to the Diabetes Industry and Market
1.2 Main Report Findings
1.3 This Study Provides the Following Knowledge
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Main Questions Answered by This Study
1.7 Who is This Study For?
1.8 Research Methods and Analysis
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain

2. Global Diabetes Drugs Market: Introduction
2.1 World Diabetes Drugs Market Segmentation
2.2 What is Diabetes?
2.3 How is Diabetes Classified?
2.4 Risk Factors, Disease Symptoms and Complications
2.5 Criteria for the Diagnosis of Diabetes
2.6 World and Regional Diabetes Incidence and Prevalence
2.7 The Economic Burden of Diabetes
2.8 Unmet Need
2.9 Leading Classes of Diabetic Medications
2.9.1 Type 1 Medication
2.9.1.1 Insulin
2.9.1.2 Surgical Options
2.9.2 Type 2 Medication
2.9.2.1 Alpha-glucosidase Inhibitors
2.9.2.2 Biguanides
2.9.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.9.2.4 Sodium-Glucose Co-Transporter 2 (SGLT2)
2.9.2.5 Thiazolidinediones
2.9.2.6 Sulfonylureas
2.9.2.7 Meglitinides
2.9.2.8 Other Injectable Medications
2.9.2.9 Combination Drug Therapies for Type 2 Diabetes

3. The World Diabetes Drugs Market, 2016-2026
3.1 The World Diabetes Drug Market, 2015
3.1.1 Diabetes Treatment Market by Drug Class, 2015
3.1.2 Top Selling Diabetes Drugs, 2015
3.1.3 Generic Anti-Diabetes Drugs, 2015
3.2 World Diabetes Drugs Market: Revenue Forecast, 2016-2026
3.3 Injectable and Non-injectable Diabetes Drugs, 2016-2026
3.3.1 Injectable Diabetes Drugs Revenue Forecast, 2016-2026
3.3.2 Non-Injectable Diabetes Drugs Revenue Forecast, 2016-2026

4. Human Insulin and Analogues, 2016-2026
4.1 Insulin and Insulin Analogues Drugs, 2015
4.2 Insulin and Insulin Analogues: Revenue Forecast, 2016-2026
4.3 Insulin and Insulin Analogues: Market Trends, 2016-2026
4.3.1 Will the Top 3 Insulin Producers Sustain Their Market Dominance?
4.3.2 New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming?
4.4 Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2016-2026
4.5 NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2016-2026
4.6 Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2016-2026
4.7 Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast, 2016-2026
4.8 Human Insulins (Novo Nordisk): Revenue Forecast, 2016-2026
4.9 NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2016-2026
4.10 Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2016-2026

5. Dipeptidyl Peptidase-4 Inhibitors (DPP-4) Market, 2016-2026
5.1 DPP-4 Market, 2015
5.2 DPP-4 Inhibitors Revenue Forecast, 2016-2026
5.3 Januvia (Sitagliptin; Merck (MSD)): Revenue Forecast, 2016-2026
5.4 Janumet (Sitagliptin and Metaformin; Merck & Co.): Revenue Forecast, 2016-2026
5.5 Galvus (Vildagliptin; Novartis): Revenue Forecast, 2016-2026
5.6 Onglyza (Saxagliptin; AstraZeneca): Revenue Forecast, 2016-2026
5.7 Nesina (Alogliptin; Takeda/Furiex Pharmaceuticals): Revenue Forecast, 2016-2026
5.8 Tradjenta (Linagliptin; Eli Lilly and Boehringer Ingelheim): Revenue Forecast, 2016-2026

6. Sulfonylureas Market, 2016-2026
6.1 Sulfonylureas Market, 2015
6.2 Sulfonylureas: Revenue Forecast 2016-2026
6.3 Sulfonylureas: Market Trends 2016-2026
6.3.1 New Opportunites for Sulfonylureas in Emerging Markets
6.3.2 Side Effects and Competitor Drugs Will Affect Sales
6.4 Diamicron (Gliclazide; Servier): Revenue Forecast, 2016-2026
6.5 Amaryl (Glimepiride; Sanofi): Revenue Forecast, 2016-2026
6.6 Glucotrol XL (Glipizide; Pfizer): Revenue Forecast, 2016-2026

7. Glucagon-Like Peptide-1 (GLP-1) Receptor agonists Market, 2016-2026
7.1 GLP-1 Receptor agonists Market, 2015
7.2 GLP-1 Receptor Agonists Revenue Forecast, 2016-2026
7.2.1 GLP-1 Receptor Agonists: Market Trends, 2016-2026
7.2.2 Promising New Approvals in the GLP-1 Class
7.2.3 GLP-1 Agonists and Weight Loss Results May Boost Revenues
7.3 Victoza (Liraglutide; Novo Nordisk): Revenue Forecast, 2016-2026
7.4 Byetta (Exenatide; AstraZeneca): Revenue Forecast, 2016-2026
7.5 Bydureon (Exenatide; AstraZeneca): Revenue Forecast, 2016-2026

8. Alpha-glucosidase Inhibitors Market, 2016-2026
8.1 Alpha-glucosidase Inhibitors Market, 2015
8.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2016-2026
8.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2016-2026
8.2.1.1 Decline of Alpha-glucosidase Inhibitors Sales Due to Side Effects
8.2.1.2 Is a New Generation of Alpha-glucosidase Inhibitors Worthwhile?
8.3 Glucobay (Acarbose; Bayer AG): Revenue Forecast, 2016-2026
8.4 Basen (Voglibose; Takeda): Revenue Forecast, 2016-2026
8.5 Glyset (Miglitol; Pfizer): Revenue Forecast, 2016-2026

9. Meglitinides Market, 2016-2026
9.1 Meglitinides Market, 2015
9.2 Meglitinides: Revenue Forecast, 2016-2026
9.2.1 Meglitinides: Market Trends, 2016-2026
9.2.1.1 Combination Therapy: New Future for Meglitinides?
9.3 Prandin (Repaglinide; Novo Nordisk): Revenue Forecast, 2016-2026
9.4 Starlix (Nateglinide; Novartis): Revenue Forecast, 2016-2026
9.5 Glufast (Acarbose; Eisai): Revenue Forecast, 2016-2026

10. Thiazolidinediones Market, 2015
11. Sodium – glucose Co-transporter (SGLT2) Inhibitors Market, 2016-2026
11.1 SGLT2 Inhibitors Market, 2015
11.2 SGLT2 Revenue Forecast, 2016-2026
11.2.1 SGLT2 Market Trends, 2016-2026
11.3 Invokana (Canagliflozin; Johnson & Johnson): Revenue Forecast, 2016-2026
11.4 Forxiga (Dapagliflozin; AstraZeneca): Revenue Forecast, 2016-2026
11.5 Jardiance (Empagliflozin; Eli Lilly): Revenue Forecast, 2016-2026

12. Biguanides Market, 2016-2026
12.1 Biguanides Market, 2015
12.2 Biguanides: Revenue Forecast: 2016-2026
12.2.1 Biguanides: Market trends, 2016-2026
12.2.2 Metformin: Delay of Diabetes
12.2.3 Higher Mortality Associated with Combined Metformin and Insulin
12.3 Glucophage (Metformin; Merck (MSD)): Revenue Forecast, 2016-2026
12.4 Glumetza (Metformin Hydrochloride; Salix Pharmaceuticals): Revenue Forecast, 2016-2026
12.5 Fortamet (Metformin; Shionogi & Co): Revenue Forecast, 2016-2026

13. National Markets for Diabetes Drugs, 2016-2026
13.1 Leading National Markets for Diabetes Drugs, 2015
13.2 Leading National Diabetes Drugs Market: Revenue Forecast, 2016-2026
13.3 The US to Sustain its Market Leadership: Revenue Forecast 2016-2026
13.3.1 High Diabetes Prevalence within a Complex Healthcare System
13.4 The Japanese Market, Revenue Forecast, 2016-2026
13.4.1 Sanofi and Takeda Collaborate to Fight Diabetes in Japan
13.4.2 Novel Treatment Options in Japan
13.5 EU5 (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2015
13.5.1 The EU5 (Germany, France, UK, Italy, Spain) Market Revenue Forecasts, 2016-2026
13.5.2 Germany: Disease Treatment Measures Require Improvement – Revenue Forecast, 2016-2026
13.5.2.1 Tough Reimbursement Rules: More Data for Faster Approval?
13.5.3 French National Diabetes Market Revenue Forecast, 2016-2026
13.5.3.1 Great Standard of Care and Regulatory Reforms in France
13.5.4 The UK National Diabetes Market Revenue Forecast, 2016-2026
13.5.4.1 Faster Approvals for New Therapies in the UK
13.5.5 Italian National Diabetes Market Revenue Forecast, 2016-2026
13.5.6 Spanish National Diabetes Market Revenue Forecast, 2016-2026
13.6 China: The World’s Largest Diabetic Population – Revenue Forecast, 2016-2026
13.6.1 Presence of Multinational Companies and the Power of Buyers
13.6.2 Disparity in Regional Health Spending
13.6.3 Multi-Billion Dollar Investment to Improve Healthcare
13.7 The Indian Market: Revenue Forecast, 2016-2026
13.7.1 Focus on the Rural Population
13.8 The Russian National Diabetes Market, 2016-2026
13.8.1 High Out of Pocket Costs Reduce Compliance
13.9 Brazil: Improved Access to Care in Rural Areas – Revenue Forecast, 2016-2026
13.9.1 Localised Insulin Production in Brazil
13.9.2 Diabetes Awareness Initiatives will Increase Market Potential

14. Diabetes Drug Market R&D Pipeline, 2016
14.1 New Diabetes Drugs Approvals and Leading Companies’ Developments, 2015-2016
14.1.1 Novo Nordisk
14.1.2 Eli Lilly & Boehringer Ingelheim
14.1.3 AstraZeneca
14.2 Human Insulins and Analogues: New Approvals
14.2.1 Insulin Glargine (Basaglar, Eli Lilly and Boehringer Ingelheim): Receives US Approval After Delays
14.2.2 Insulin Glargine (Toujeo, Sanofi): Will it Replace Lantus?
14.2.3 Afrezza (Sanofi and MannKind): The First Inhaled Insulin Fails to Make an Impact
14.3 Human Insulins and Analogues: Pipeline Developments: New Approvals
14.3.1 Tresiba (Novo Nordisk): Opportunity Revival
14.3.2 MK-1293 (Merck (MSD) and Biogen Idec): Will Provide more Biosimilar Competition for Lantus
14.3.3 NN9924 (Novo Nordisk)
14.3.4 BIOD-123 (Biodel)
14.4 DPP-4 Inhibitors: Pipeline Developments
14.4.1 Zafatek (Trelagliptin Succinate; Takeda and Furiex Pharmaceuticals): Approved in Japan
14.4.2 Omarigliptin (MK-3102; Merck (MSD))
14.5 GLP-1: New Approvals and Pipeline, 2016
14.5.1 Trulicity (Dulaglutide; Eli Lilly): Potential for Blockbuster Status
14.5.2 Semaglutide (NN9535; Novo Nordisk)
14.5.3 Xultophy (IdegLira; Novo Nordisk)
14.5.4 ITCA 650 (Intarcia Theraputics)
14.6 Sodium Glucose Co-Transporter 2: Pipeline Developments, 2016
14.6.1 Sotagliflozin (Lexicon Pharmacuticals)
14.6.2 Apleway (Tofogliflozin; Sanofi/Takeda)
14.6.3 MK8835 (Ertugliflozin; Merck (MSD))
14.6.4 Bexagliflozin (Theracos)
14.7 Other Diabetes Drugs: Pipeline Developments, 2016
14.7.1 DM199 (DiaMedica)
14.7.2 Glucokinase Activators
14.7.2.1 LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)

15. Diabetes Drugs: World Industry, Market and R&D Analysis, 2016-2026
15.1 SWOT Analysis of the Diabetes Drug Market, 2016-2026
15.2 Strengths
15.2.1 Promising Research and Development
15.2.2 Secondary Indications
15.2.3 Biological Drugs are Tougher to copy and Offer Variety
15.2.4 Market Competition
15.3 Weaknesses
15.3.1 Lack of Disease Awareness
15.3.2 Tougher Reimbursement Rules
15.3.3 Increased Risk of Cardiovascular Complications
15.3.4 Rising Cost of Drug Development
15.4 Opportunities
15.4.1 Rising Disease Prevalence
15.4.2 Emerging National Markets Hold Great Potential
15.4.3 Novel Insulin Delivery Methods
15.4.4 New Classes of Anti Diabetes Drugs
15.5 Threats
15.5.1 Type 1 Diabetes Vaccine
15.5.2 Increased Popularity of Other Therapies
15.5.3 Generic Drugs: Patent Expiries and Rising Competition
15.5.4 Regulatory Barriers – Challenges Getting Drug Approval
15.6 STEP Analysis of the World Diabetes Drugs Market, 2016-2026
15.6.1 Social Developments
15.6.2 Technological Advances
15.6.3 Economic Factors
15.6.4 Political Issues

16. Research Interviews
16.1 Interview with Professor Mark Baker, Clinical Practice Director of the National Institute of Healthcare Excellence (NICE)

17. Conclusions from the Research and Analysis
17.1 The Diabetes Market – Trends Shaping Those Treatments
17.2 Outlook of the Worlds Diabetes Drug Industry, 2016-2026
17.3 Insulin Will Continue to Dominate the Market
17.4 National Diabetes Market Outlooks, 2016-2026
17.5 Future Opportunities

Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form

List of Tables
Table 1.1 Leading National Diabetes Drugs Markets: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 2.1 Types of Injectable Insulin, 2016
Table 2.2 Oral Drug Classes for Type 2 Diabetes, 2016
Table 2.3 Other Injectable Drugs for Type 2 Diabetes, 2016
Table 2.4 Combination Drug Therapies for Type 2 Diabetes, 2016
Table 3.1 World Diabetes Drugs Market: Revenue ($m) and Market Share (%) by Type of Medication, 2015
Table 3.2 World Diabetes Drugs Market: Sales ($m) and Market Share (%) by Drugs Class, 2015
Table 3.3 Top 10 Diabetes Drugs Sales ($m), 2015
Table 3.4 World Diabetes Drugs Market: Revenue Forecasts ($m) by Drug Class, 2016-2026
Table 3.5 Injectable Diabetes Drugs: Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 3.6 Non-Injectable Diabetes Drugs: Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 4.1 Human Insulins and Analogues: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015
Table 4.2 Leading Human Insulin and Analogue Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.3 Top 3 Insulin Drug Producers: Insulin Portfolio, Sales ($m), and Insulin Submarket Share (%), 2015
Table 4.4 Lantus: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 4.5 NovoLog: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 4.6 Humalog: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 4.7 Levemir: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 4.8 Human Insulin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 4.9 NovoMix: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 4.10 Humulin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 5.1 DPP-4 Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015
Table 5.2 Leading DPP-4 Inhibitor Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 5.3 Januvia: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 5.4 Janumet: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 5.5 Galvus: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 5.6 Onglyza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 5.7 Nesina: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 5.8 Tradjenta: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 6.1 Sulfonylureas: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015
Table 6.2 Leading Sulfonylureas Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 6.3 Diamicron: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 6.4 Amaryl: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 6.5 Glucotrol: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 7.1 GLP-1: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015
Table 7.2 Leading GLP-1 Receptor Agonists: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 7.3 Victoza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 7.4 Byetta: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 7.5 Bydureon: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 8.1 Alpha-glucosidase Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015
Table 8.2 Leading Alpha-glucosidase Inhibitors: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 8.3 Glucobay: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 8.4 Basen: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 8.5 Glyset: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 9.1 Meglitinides: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015
Table 9.2 Leading Meglitinides: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 9.3 Prandin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 9.4 Starlix: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 9.5 Glufast: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 10.1 Thiazolidinediones: Revenues ($m), 2015
Table 11.1 SGLT2 Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015
Table 11.2 Leading SGLT2 Inhibitors: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 11.3 Invokana: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 11.4 Forxiga: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 11.5 Jardiance: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 12.1 Biguanides: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015
Table 12.2 Leading Biguanides: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 12.3 Glucophage: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 12.4 Glumetza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 12.5 Fortamet: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026
Table 13.1 The Global Diabetes Drugs Market: Revenues ($m) and Market Shares (%) by Region, 2015
Table 13.2 Leading National Diabetes Drugs Markets: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 13.3 The US: Drug Revenue Forecast ($m),Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 13.4 The Japan: Drug Revenue Forecast ($m),Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 13.5 EU5 (Germany, France, UK, Italy, Spain) Market: Revenue ($m), EU5 Market Share (%) and Global Market Share, 2015
Table 13.6 Leading National Diabetes Drugs Markets: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 13.7 Germany: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 13.8 France: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 13.9 The UK: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 13.10 Italy: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 13.11 Spain: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 13.12 China: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 13.13 India: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 13.14 Russia: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 13.15 Brazil: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026
Table 14.1 FDA Approvals for Anti Diabetes Drugs, 2015 and 2016

List of Figures
Figure 2.1 Diabetes Drugs Market Segmentation Overview, 2016
Figure 2.2 Diabetes Drugs Market Segmentation Overview, 2016
Figure 2.3 Diabetes Types and Classification, 2016
Figure 2.4 Causes of Diabetes, 2016
Figure 2.5 Prevalence of Diabetes in Leading Economic Countries, 2015
Figure 3.1 World Diabetes Drugs Market: Market Share (%) by Type of Medication, 2015
Figure 3.2 World Diabetes Drugs Market: Market Shares (%) by Drug Class, 2015
Figure 3.3 Top 10 Diabetes Drugs by Market Share (%), 2015
Figure 3.4 World Diabetes Drugs Market: Revenue Forecast ($m), 2016-2026
Figure 3.5 World Diabetes Drugs Market: AGR Forecast (%), 2016-2026
Figure 3.6 Injectable Diabetes Drugs: Revenue Forecast ($m), 2016-2026
Figure 3.7 Injectable Diabetes Drugs: AGR Forecast (%), 2016-2026
Figure 3.8 Non-Injectable Diabetes Drugs: Revenue Forecast ($m), 2016-2026
Figure 3.9 Non-Injectable Diabetes Drugs: AGR Forecast (%), 2016-2026
Figure 4.1 Human Insulins and Analogues: Market Shares (%) for Leading Drugs, 2015
Figure 4.2 Insulin and Insulin Analogues Market: Revenue Forecast ($m), 2016-2026
Figure 4.3 Insulin and Insulin Analogues Market: AGR Forecast (%), 2016-2026
Figure 4.4 Lantus: Drug Revenue Forecast ($m), 2016-2026
Figure 4.5 Lantus: AGR Forecast (%), 2016-2026
Figure 4.6 NovoLog: Drug Revenue Forecast ($m), 2016-2026
Figure 4.7 NovoLog: AGR Forecast (%), 2016-2026
Figure 4.8 Humalog: Drug Revenue Forecast ($m), 2016-2026
Figure 4.9 Humalog: AGR Forecast (%), 2016-2026
Figure 4.10 Levemir: Drug Revenue Forecast ($m), 2016-2026
Figure 4.11 Levemir: AGR Forecast (%), 2016-2026
Figure 4.12 Human Insulins: Drug Revenue Forecast ($m), 2016-2026
Figure 4.13 Human Insulins: AGR Forecast (%), 2016-2026
Figure 4.14 NovoMix: Drug Revenue Forecast ($m), 2016-2026
Figure 4.15 NovoMix: AGR Forecast (%), 2016-2026
Figure 4.16 Humulin: Drug Revenue Forecast ($m), 2016-2026
Figure 4.17 Humulin: AGR Forecast (%), 2016-2026
Figure 5.1 DPP-4 Inhibitors: Market Shares (%) for Leading Drugs, 2015
Figure 5.2 DPP-4 Inhibitors: Sales ($m) for Leading Drugs, 2015
Figure 5.3 DPP-4 Inhibitor Drugs Market: Revenue Forecast ($m), 2016-2026
Figure 5.4 DPP-4 Inhibitor Drugs Market: AGR Forecast (%), 2016-2026
Figure 5.5 Januvia: Drug Revenue Forecast ($m), 2016-2026
Figure 5.6 Januvia: AGR Forecast (%), 2016-2026
Figure 5.7 Janumet: Drug Revenue Forecast ($m), 2016-2026
Figure 5.8 Janumet: AGR Forecast (%), 2016-2026
Figure 5.9 Galvus: Drug Revenue Forecast ($m), 2016-2026
Figure 5.10 Galvus: AGR Forecast (%), 2016-2026
Figure 5.11 Onglyza: Drug Revenue Forecast ($m), 2016-2026
Figure 5.12 Onglyza: AGR Forecast (%), 2016-2026
Figure 5.13 Nesina: Drug Revenue Forecast ($m), 2016-2026
Figure 5.14 Nesina: AGR Forecast (%), 2016-2026
Figure 5.15 Tradjenta: Drug Revenue Forecast ($m), 2016-2026
Figure 5.16 Tradjenta: AGR Forecast (%), 2016-2026
Figure 6.1 Sulfonylureas: Market Shares (%) for Leading Drugs, 2015
Figure 6.2 Sulfonylureas: Sales ($m) for Leading Drugs, 2015
Figure 6.3 Sulfonylureas: Drug Revenue Forecast ($m), 2016-2026
Figure 6.4 Sulfonylureas: AGR Forecast (%), 2016-2026
Figure 6.5 Diamicron: Drug Revenue Forecast ($m), 2016-2026
Figure 6.6 Diamicron: AGR Forecast (%), 2016-2026
Figure 6.7 Amaryl: Drug Revenue Forecast ($m), 2016-2026
Figure 6.8 Amaryl: AGR Forecast (%), 2016-2026
Figure 6.9 Glucotrol: Drug Revenue Forecast ($m), 2016-2026
Figure 6.10 Glucotrol: AGR Forecast (%), 2016-2026
Figure 7.1 GLP-1: Market Shares (%) for Leading Drugs, 2015
Figure 7.2 GLP-1: Revenue ($m) for Leading Drugs, 2015
Figure 7.3 GLP-1 Receptor Agonists: Revenue Forecast ($m), 2016-2026
Figure 7.4 GLP-1 Receptor Agonists: AGR Forecast (%), 2016-2026
Figure 7.5 Victoza: Drug Revenue Forecast ($m), 2016-2026
Figure 7.6 Victoza: AGR Forecast (%), 2016-2026
Figure 7.7 Byetta: Drug Revenue Forecast ($m), 2016-2026
Figure 7.8 Byetta: AGR Forecast (%), 2016-2026
Figure 7.9 Bydureon: Drug Revenue Forecast ($m), 2016-2026
Figure 7.10 Bydureon: AGR Forecast (%), 2016-2026
Figure 8.1 Alpha-glucosidase Inhibitors: Market Shares (%) for Leading Drugs, 2015
Figure 8.2 Alpha-glucosidase Inhibitors: Revenue Sales ($m), 2015
Figure 8.3 Alpha-glucosidase Inhibitors: Revenue Forecast ($m), 2016-2026
Figure 8.4 Alpha-glucosidase Inhibitors: AGR Forecast (%), 2016-2026
Figure 8.5 Glucobay: Drug Revenue Forecast ($m), 2016-2026
Figure 8.6 Glucobay: AGR Forecast (%), 2016-2026
Figure 8.7 Basen: Drug Revenue Forecast ($m), 2016-2026
Figure 8.8 Basen: AGR Forecast (%), 2016-2026
Figure 8.9 Glyset: Drug Revenue Forecast ($m), 2016-2026
Figure 8.10 Glyset: AGR Forecast (%), 2016-2026
Figure 9.1 Meglitinides: Market Shares (%) for Leading Drugs, 2015
Figure 9.2 Meglitinides: Market Sales ($m) for Leading Drugs, 2015
Figure 9.3 Meglitinides: Revenue Forecast ($m), 2016-2026
Figure 9.4 Meglitinides: AGR Forecast (%), 2016-2026
Figure 9.5 Prandin: Drug Revenue Forecast ($m), 2016-2026
Figure 9.6 Prandin: AGR Forecast (%), 2016-2026
Figure 9.7 Starlix: Drug Revenue Forecast ($m), 2016-2026
Figure 9.8 Starlix: AGR Forecast (%), 2016-2026
Figure 9.9 Glufast: Drug Revenue Forecast ($m), 2016-2026
Figure 9.10 Glufast: AGR Forecast (%), 2016-2026
Figure 10.1 Thiazolidinediones: Revenues ($m), 2015
Figure 11.1 SGLT2 Inhibitors: Market Share (%) for Leading Drugs, 2015
Figure 11.2 SGLT2 Inhibitors: Sales ($m) for Leading Drugs, 2015
Figure 11.3 SGLT2 Inhibitors: Revenue Forecast ($m), 2016-2026
Figure 11.4 SGLT2 Inhibitors: AGR Forecast (%), 2016-2026
Figure 11.5 Invokana: Drug Revenue Forecast ($m), 2016-2026
Figure 11.6 Invokana: AGR Forecast (%), 2016-2026
Figure 11.7 Forxiga: Drug Revenue Forecast ($m), 2016-2026
Figure 11.8 Forxiga: AGR Forecast (%), 2016-2026
Figure 11.9 Jardiance: Drug Revenue Forecast ($m), 2016-2026
Figure 11.10 Jardiance: AGR Forecast (%), 2016-2026
Figure 12.1 Biguanides: Market Shares (%) for Leading Drugs, 2015
Figure 12.2 Biguanides: Revenue ($m) for Leading Drugs, 2015
Figure 12.3 Biguanides: Revenue Forecast ($m), 2016-2026
Figure 12.4 Biguanides: AGR Forecast (%), 2016-2026
Figure 12.5 Glucophage: Drug Revenue Forecast ($m), 2016-2026
Figure 12.6 Glucophage: AGR Forecast (%), 2016-2026
Figure 12.7 Glumetza: Drug Revenue Forecast ($m), 2016-2026
Figure 12.8 Glumetza: AGR Forecast (%), 2016-2026
Figure 12.9 Fortamet: Drug Revenue Forecast ($m), 2016-2026
Figure 12.10 Fortamet: AGR Forecast (%), 2016-2026
Figure 13.1 The Global Diabetes Drugs Market: Revenues ($m) by Region, 2015
Figure 13.2 The Global Diabetes Drugs Market: Market Shares (%) by Region, 2015
Figure 13.3 The US Diabetes Drugs Market: Revenue Forecast ($m), 2016-2026
Figure 13.4 The US Diabetes Drugs Market: AGR Forecast (%), 2016-2026
Figure 13.5 The Japanese Diabetes Drugs Market: Revenue Forecast ($m), 2016-2026
Figure 13.6 The Japanese Diabetes Drugs Market: AGR Forecast (%), 2016-2026
Figure 13.7 The EU5 (Germany, France, UK, Italy, Spain) Countries: Revenue ($m) by Country, 2015
Figure 13.8 EU5 (Germany, France, UK, Italy, Spain) Countries: EU5 Market Shares (%) by Country, 2015
Figure 13.9 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($m), 2016-2026
Figure 13.10 EU5 (Germany, France, UK, Italy, Spain): AGR Forecast (%), 2016-2026
Figure 13.11 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts by Country ($m), 2016-2026
Figure 13.12 Germany: Revenue Forecast ($m), 2016-2026
Figure 13.13 Germany: AGR Forecast (%), 2016-2026
Figure 13.14 France: Revenue Forecast ($m), 2016-2026
Figure 13.15 France: AGR Forecast (%), 2016-2026
Figure 13.16 UK: Revenue Forecast ($m), 2016-2026
Figure 13.17 UK: AGR Forecast (%), 2016-2026
Figure 13.18 Italy: Revenue Forecast ($m), 2016-2026
Figure 13.19 Italy: AGR Forecast (%), 2016-2026
Figure 13.20 Spain: Revenue Forecast ($m), 2016-2026
Figure 13.21 Spain: AGR Forecast (%), 2016-2026
Figure 13.22 China: Revenue Forecast ($m), 2016-2026
Figure 13.23 China: AGR Forecast (%), 2016-2026
Figure 13.24 India: Revenue Forecast ($m), 2016-2026
Figure 13.25 India: AGR Forecast (%), 2016-2026
Figure 13.26 Russia: Revenue Forecast ($m), 2016-2026
Figure 13.27 Russia: AGR Forecast (%), 2016-2026
Figure 13.28 Brazil: Revenue Forecast ($m), 2016-2026
Figure 13.29 Brazil: AGR Forecast (%), 2016-2026
Figure 15.1 SWOT Analysis of the World Diabetes Drugs Market, 2016-2026
Figure 15.2 STEP Analysis of the World Diabetes Drugs Market, 2016-2026
Figure 17.1 Revenue for the Main Diabetes Drugs Classes ($m), 2015, 2020 and 2026
Figure 17.2 Revenue for the Main National Diabetes Markets ($m), 2015, 2020 and 2026

★調査レポート[糖尿病治療薬の世界市場2016-2026]販売に関する免責事項
★調査レポート[糖尿病治療薬の世界市場2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆